(E)-hept-3-ene-2,5-dione | 82782-04-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (E)-hept-3-ene-2,5-dione
• 英文别名: 3E-Hepten-2,5-dione
• CAS: 82782-04-5
• 化学式: C₇H₁₀O₂
• 分子量: 126.155
• InChiKey: YTVSAHBJOWKZHT-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  甲醇 、 (E)-hept-3-ene-2,5-dione 在 sodium hydroxide 作用下， 反应 48.0h， 以83%的产率得到4-methoxy-2,3-dimethyl-2-cyclopentenone
  参考文献：
  名称：

  Andersen, Soeren H.; Das, Nalin B.; Joergensen, Ruth D., Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1982, vol. 36, # 1, p. 1 - 14

  摘要：

  DOI：
• 作为产物：
  描述：

  (4E)-4-庚烯-2-酮 在 (5,10,15,20-tetraphenylporphyrinato)manganese(III) chloride 、 氧气 、 三乙胺 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 2.0h， 以25%的产率得到(E)-hept-3-ene-2,5-dione
  参考文献：
  名称：

  Oxidation of β,γ-Unsaturated Ketones with Molecular Oxygen Catalyzed by Metal Phthalocyanines and Porphyrins: A Practical Synthesis of Oxophorone

  摘要：

  金属酞菁 (Pc) 和 5,10,15,20-四苯基卟啉 (TPP)（包括 Mn(II)、Mn）催化分子氧氧化 3,5,5-三甲基环己-3-en-1-酮 (1) (III)、Fe(II)、Fe(III)、Co(II)、Cu(II) 和 Ru(II) 生成 3,5,5-三甲基环己-2-烯-1,4-二酮 (2)被研究了。 TPPMn(III)Cl表现出优异的催化活性，2的产率高达93%，周转数为1200。

  DOI：

  10.1055/s-1997-1165

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
  申请人：Kandula Mahesh

  公开号：US20160090350A1

  公开（公告）日：2016-03-31

  The invention relates to the compounds of formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and other inflammatory diseases.

  本发明涉及式II化合物及其药学上可接受的盐、多晶体、溶剂化物、对映体、立体异构体和水合物。含有式II化合物的有效量的药物组合物可以制成口服、颊粘、直肠、局部、经皮、经黏膜、静脉、全身给药、糖浆或注射剂型，用于治疗或预防多发性硬化症。这样的组合物可以用于治疗神经退行性疾病和其他炎症性疾病。
• Diarylphenoxy Aluminum Compounds
  申请人：Friedrich Marko

  公开号：US20080167504A1

  公开（公告）日：2008-07-10

  The present invention relates to diarylphenoxyaluminum compounds which are obtainable by reacting a bis(diarylphenol) ligand of the formula (I) with an alkylaluminum compound and/or a complex aluminum hydride. The invention moreover relates to the use of such diarylphenoxyaluminum compounds as catalysts. Moreover, the invention relates to a method of producing isopulegol by cyclization of citronellal in the presence of diarylphenoxyaluminum compounds as catalysts. The invention also relates to a method of producing menthol by cyclization of citronellal in the presence of diarylphenoxyaluminum compounds as catalysts and subsequent hydrogenation.

  本发明涉及通过将式（I）的双（二芳基酚）配体与一种烷基铝化合物和/或复合铝氢化物反应而得到的二芳基苯氧基铝化合物。此外，本发明还涉及使用这种二芳基苯氧基铝化合物作为催化剂的方法。此外，本发明还涉及在二芳基苯氧基铝化合物存在的情况下通过环化香叶醛来生产异莰醇的方法。本发明还涉及在二芳基苯氧基铝化合物存在的情况下通过环化香叶醛并随后进行氢化来生产薄荷醇的方法。
• Highly Stereoselective Diels–Alder Reactions Catalyzed by Diboronate Complexes**
  作者：Yuan‐He Li、Su‐Lei Zhang、Yong Lu、Bo Xiao、Tian‐Yu Sun、Qian‐Qian Xu、Jia‐Hua Chen、Zhen Yang

  DOI：10.1002/anie.202303075

  日期：2023.8.14

  diboronates (BPDB) is reported. Under Lewis acid activation, they can catalyze highly exo-selective and enantioselective Diels–Alder reactions. For diactivated dienophiles, BPDB can also selectively activate one of the two carbonyl groups based on steric effect, resulting in highly regioselective asymmetric Diels–Alder reactions.

  报道了一系列易于合成、空气和水分稳定的新化合物，称为双吡咯烷二硼酸盐（BPDB）。在路易斯酸活化下，它们可以催化高度外型选择性和对映选择性狄尔斯-阿尔德反应。对于双活化亲双烯体，BPDB 还可以基于空间效应选择性地激活两个羰基之一，从而导致高度区域选择性的不对称狄尔斯-阿尔德反应。
• Skatteboel, Lars; Stenstroem, Yngve, Acta Chemica Scandinavica, 1995, vol. 49, # 7, p. 543 - 545
  作者：Skatteboel, Lars、Stenstroem, Yngve

  DOI：——

  日期：——
• BIOABSORBABLE ELASTOMERIC ARTERIAL SUPPORT DEVICE AND METHODS OF USE
  申请人：Carpenter Kenneth W.

  公开号：US20090022772A1

  公开（公告）日：2009-01-22

  The invention provides bioabsorbable elastomeric arterial support devices fabricated using elastomeric polymer networks and semi-interpenetrating networks in which a linear polymer is crosslinked by ester or alpha-amino-acid containing cross-linkers that polymerize upon exposure to active species. The invention devices are designed for implant into curved segments of artery and can be expanded during arterial implant and cross-linked in vivo in the expanded state to restore a clogged artery to extended function. The invention devices are useful for in vivo implant in diseased arteries and for delivery of a variety of therapeutic molecules in a time release fashion to surrounding tissues to reduce or eliminate arterial response to implant of the device.